From anto.ilmago from gmail.com Thu Feb 21 11:49:21 2008 From: anto.ilmago from gmail.com (AR) Date: Thu Feb 21 13:37:34 2008 Subject: [Immunology] PD-1 Message-ID: I've recently tried a PE-conjugated anti human PD-1 antibody, to stain some human PBMCs in inflammatory and autoimmune conditions. Some published papers use a FITC-conjugated antibody, same clone as mine (MIH4), but the graphs for their staining show an increased signal compared to mine. Could it be possible that the PE conjugation affects the binding of the antibody, reducing its specificity compared to FITC? Waiting for some replies... Thanks in advance :-) AR From jayaseelan_74 from yahoo.com Thu Feb 21 14:35:35 2008 From: jayaseelan_74 from yahoo.com (jayaseelan murugaiyan) Date: Thu Feb 21 19:20:11 2008 Subject: [Immunology] Jurkat T cell stimulation In-Reply-To: Message-ID: <310839.26602.qm@web32507.mail.mud.yahoo.com> Hi, Recently, I am involved in nonspecific stimulation of Jurkat T cells with 10 ng/ml of PMA and 1 ?M of Ionomycin. After 4 hours of incubation in CO2 incubator shows a decline in cell number. After 24 hours of incubation, I noticed a cell death up to 60% and IL-2 assay production was up to 90 pg/106 cells. I would be happy, if some of suggest me, whether, I should find increase in cell number along with the IL-2 production. I am looking forward for your valuable suggestions. Thank you for your understanding. With regards Jayaseelan ____________________________________________________________________________________ Be a better friend, newshound, and know-it-all with Yahoo! Mobile. Try it now. http://mobile.yahoo.com/;_ylt=Ahu06i62sR8HDtDypao8Wcj9tAcJ From tdenysse from bccrc.ca Tue Feb 26 18:05:41 2008 From: tdenysse from bccrc.ca (Tetyana Denyssevych) Date: Tue Feb 26 22:02:39 2008 Subject: [Immunology] ELISA: blanking and data interpretation question Message-ID: <5F05ADF094FDB749A9559AA84FBEDCF6026CB4D5@crcmail1.BCCRC.CA> Hello everybody, I have a question on how to blank the results from a typical double sandwich ELISA assay. The assay measures therapeutic antibody in human serum and I have two blanks available : assay buffer and calibrator "Zero" containing 0.05% of human serum (after MRD 1:2000) and no analyte. So far I was blanking all results only with the assay buffer value. Is this totally incorrect? I was assuming that calibrator "Zero" should be part of the calibration curve. If standard "Zero" should be used as a blank, then how to construct the standard curve in the 4PL model? It would mean that standard zero is not included in the model. Would this be a correct approach? Thank you for your help in this educational exercise t QC Officer, Investigational Drug Program BC Cancer Agency phone: 604-675-8000, ext 7026 fax: 604-675-8183 e-mail: tdenysse@bccrc.ca From J.Budukiewicz from natureny.com Thu Feb 28 11:56:42 2008 From: J.Budukiewicz from natureny.com (Budukiewicz, Joanna) Date: Thu Feb 28 15:15:04 2008 Subject: [Immunology] Multiple Sclerosis Conference June 6, 2008- Paris, France Message-ID: Fondation IPSEN, Nature Medicine and Nature Immunology present: Multiple Sclerosis: From Pathogenesis to Therapy June 6, 2008 Espace Charles Louis Havas, Paris, France This mini-symposium will address open questions in multiple sclerosis research, with the goal of identifying future directions that may lead to therapy. Application Deadline: March 31, 2008 Attendance at this meeting is free on acceptance of application. To apply and for more information visit: www.nature.com/natureconferences/eandc/MS